PRNewswire (Wed, 3-Jun 8:00 AM ET)
Fresenius Medical Care launches first tranche of its share buyback program of up to EUR 600 million
PRNewswire (Thu, 28-May 7:00 AM ET)
Fresenius Medical Care highlights new renal research and innovation at ERA Congress 2026
PRNewswire (Wed, 27-May 9:05 AM ET)
PRNewswire (Tue, 26-May 7:00 AM ET)
PRNewswire (Thu, 21-May 10:14 AM ET)
Fresenius Medical Care Reappoints Chief Financial Officer Martin Fischer
PRNewswire (Wed, 20-May 1:01 PM ET)
Market Chameleon (Tue, 5-May 5:21 AM ET)
PRNewswire (Tue, 5-May 7:00 AM ET)
Fresenius Medical Care Achieves Double-Digit Margin and Record Earnings Growth in 2025
Market Chameleon (Tue, 24-Feb 3:19 AM ET)
Market Chameleon (Tue, 4-Nov 3:29 AM ET)
Fresenius Medical Care is the largest dialysis company in the world, treating nearly 300,000 patients from about 3,600 clinics worldwide as of December 2025. In addition to providing dialysis services, the firm is a leading supplier of dialysis products, including machines, dialyzers, and concentrates. Fresenius accounts for about 35% of the global dialysis products market, creating the world's only fully integrated dialysis business. Services account for about three-fourths of sales, while the balance is generated from medical technology products that enable dialysis treatments.
Fresenius Medical Care Ag American Depositary Shares (Each Representing 1/2 Of An Ordinary Share) trades on the NYSE stock market under the symbol FMS.
As of July 13, 2026, FMS stock price climbed to $24.45 with 480,310 million shares trading.
FMS has a beta of 0.54, meaning it tends to be less sensitive to market movements. FMS has a correlation of 0.08 to the broad based SPY ETF.
FMS has a market cap of $13.13 billion. This is considered a Large Cap stock.
Last quarter Fresenius Medical Care Ag American Depositary Shares (Each Representing 1/2 Of An Ordinary Share) reported $5 billion in Revenue and $.53 earnings per share. This fell short of revenue expectation by $-319 million and missed earnings estimates by -$.06.
In the last 3 years, FMS traded as high as $30.46 and as low as $16.37.
The top ETF exchange traded funds that FMS belongs to (by Net Assets): PZLV, APIE, AVDE, TIIV, CVAR.
FMS has underperformed the market in the last year with a return of -7.8%, while the SPY ETF gained +20.9%. In the last 3 month period, FMS fell short of the market, returning +7.2%, while SPY returned +10.5%. However, in the most recent 2 weeks FMS has outperformed the stock market by returning +5.2%, while SPY returned +2.8%.
FMS support price is $23.64 and resistance is $24.40 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that FMS shares will trade within this expected range on the day.